Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Consilient Health Limited, 5th Floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland
GHRYVELIN 60 mg granules for oral suspension in sachet.
| Pharmaceutical Form |
|---|
|
Granules for oral suspension in sachet. White to off-white granules. |
Each sachet contains 60 mg macimorelin (as acetate). 1 mL of the reconstituted suspension contains 500 micrograms macimorelin.
Excipient(s) with known effect:
Contains lactose monohydrate 1,691.8 mg per sachet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Macimorelin |
Macimorelin is an orally available peptidomimetic with growth hormone (GH) secretagogue activity similar to ghrelin. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors (GHSR) present in the pituitary and hypothalamus. |
| List of Excipients |
|---|
|
Lactose monohydrate |
One LDPE/Alu/LDPE/paper sachet containing 1,817 mg granules placed in cardboard box.
Each cardboard box contains 1 sachet.
Consilient Health Limited, 5th Floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland
EU/1/18/1337/001
Date of first registration: 11 January 2019
| Drug | Countries | |
|---|---|---|
| GHRYVELIN | Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
